Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2018 | Defibrotide: still early days but a promising outlook for veno-occlusive disease

Defibrotide has previously been studied in post-stem cell transplant patients with veno-occlusive disease with a suitable investigational new drug (IND). Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Paul Richardson, MD, of the Dana-Farber Cancer Institute, Boston, MA, explains how over 700 patients took part in the expanded access T-IND study (NCT00628498), and that the results obtained to date have been quite promising. Dr Richardson emphasizes just how optimistic these results are by comparing them to the results of previous drugs studied in this manner, and concludes his interview by mentioning the safety and efficacy of the drug.